Dean Capital Investments Management LLC bought a new stake in shares of Envista Holdings Corporation (NASDAQ:NVST) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 21,467 shares of the company’s stock, valued at approximately $598,000.
Other institutional investors and hedge funds have also modified their holdings of the company. Massachusetts Financial Services Co. MA purchased a new position in shares of Envista in the 3rd quarter worth approximately $55,215,000. Tower Research Capital LLC TRC purchased a new position in Envista during the 3rd quarter valued at $46,000. SG Americas Securities LLC purchased a new position in Envista during the 3rd quarter valued at $173,000. Eos Focused Equity Management L.P. purchased a new position in Envista during the 3rd quarter valued at $1,723,000. Finally, Oppenheimer Asset Management Inc. purchased a new position in Envista during the 3rd quarter valued at $218,000.
In other Envista news, CEO Amir Aghdaei bought 10,000 shares of Envista stock in a transaction that occurred on Friday, September 20th. The shares were bought at an average cost of $22.00 per share, with a total value of $220,000.00. Also, CFO Howard H. Yu bought 2,000 shares of Envista stock in a transaction that occurred on Friday, September 20th. The shares were acquired at an average cost of $22.00 per share, for a total transaction of $44,000.00. Over the last three months, insiders bought 13,000 shares of company stock valued at $286,000.
NASDAQ NVST traded down $0.05 on Tuesday, reaching $28.25. 1,516 shares of the stock traded hands, compared to its average volume of 888,982. Envista Holdings Corporation has a 12 month low of $25.65 and a 12 month high of $30.80. The stock’s fifty day simple moving average is $28.37.
Envista (NASDAQ:NVST) last released its quarterly earnings results on Thursday, October 24th. The company reported $0.47 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.43 by $0.04. The company had revenue of $659.30 million during the quarter, compared to the consensus estimate of $669.45 million. Envista’s revenue for the quarter was down 3.0% on a year-over-year basis.
Envista Holdings Corporation manufactures and sells dental products in the United States and internationally. The company's Specialty Products & Technologies segment provides dental implant systems, guided surgery systems, biomaterials, prefabricated and custom-built prosthetics, and dental eye loupes to oral surgeons, prosthodontists, and periodontists under the brands, including Nobel Biocare, Alpha Bio Tec, Implant Direct, Nobel Procera, and Orascoptic; and brackets and wires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products under the Ormco, Insignia, AOA, and Spark brands.
Read More: How to Use the New Google Finance Tool
Want to see what other hedge funds are holding NVST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Envista Holdings Corporation (NASDAQ:NVST).
Receive News & Ratings for Envista Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envista and related companies with MarketBeat.com's FREE daily email newsletter.